FOR RESEARCH SCIENTIFIC STUDIES ONLY- NOT FOR HUMAN/ANIMAL CONSUMPTION/USE
Every batch of Labrat Peptides undergoes third-party Mass Spectrometry and HPLC analysis. We believe in absolute transparency - since in third-party marketing we need complete confidence.
Cagrilintide 10MG is a synthetic peptide research material associated with experimental investigation of amylin signaling, metabolic regulation, appetite-related pathways, energy balance, glucose physiology, and body-weight biology.
Cagrilintide is a long-acting amylin analogue that has been investigated in clinical and preclinical research. Amylin is a peptide hormone produced by pancreatic beta cells and is involved in physiological processes related to meal-related signaling, gastric emptying, satiety, and glucose regulation.
The development of cagrilintide has attracted considerable scientific interest because it represents a distinct biological pathway from the GLP-1 receptor pathway. Cagrilintide has also been studied in combination with semaglutide, where the two compounds engage complementary biological mechanisms. The combination is known as CagriSema. New England Journal of Medicine
The 10MG presentation provides a defined quantity of research material for qualified laboratory investigation.
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.
Cagrilintide is a long-acting analogue of amylin, a hormone naturally produced by pancreatic beta cells.
Amylin participates in several physiological processes, including:
Because of these biological functions, amylin signaling has become an important area of metabolic research.
Cagrilintide has been developed as a longer-acting amylin analogue and has been investigated in controlled clinical trials. In the phase 3 REDEFINE 1 program, cagrilintide was evaluated alongside semaglutide, the combination product, and placebo. New England Journal of Medicine
Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells.
Research into amylin biology examines how this signaling system contributes to:
The amylin pathway is particularly interesting because it complements other metabolic signaling systems.
Researchers can investigate amylin-related pathways using biochemical, cellular, physiological, and clinical research models.
Amylin signaling involves receptor complexes associated with the calcitonin receptor and receptor activity-modifying proteins.
Experimental research can investigate:
Understanding these pathways can provide insight into how amylin-related signals influence physiological responses following food intake.
Satiety is influenced by a network of hormonal, neural, and gastrointestinal signals.
Researchers studying appetite biology may examine:
Amylin is one component of this complex regulatory network.
Experimental investigation of long-acting amylin analogues can therefore contribute to a broader understanding of appetite and energy-balance biology.
Energy balance represents the relationship between energy intake and energy expenditure.
Research in this field can examine:
Cagrilintide research has been incorporated into broader studies examining changes in body weight and metabolic parameters.
The scientific value of such research extends beyond any single endpoint because energy balance is controlled by multiple interacting systems.
Metabolic research examines how organisms regulate nutrients and energy.
Important areas include:
Cagrilintide provides researchers with an experimental tool for studying the amylin component of this broader metabolic network.
Amylin is physiologically associated with insulin secretion and post-meal glucose regulation.
Researchers can investigate:
The interaction between amylin and insulin is an important subject within metabolic physiology.
Experimental studies may examine these pathways independently or in combination with other metabolic signals.
Gastric emptying is the process through which stomach contents move into the small intestine.
It can influence:
Amylin biology has been associated with regulation of gastric emptying, making this an important area for amylin-related research.
Researchers can use validated physiological techniques to investigate gastric motility and related responses.
One of the most extensively studied applications of cagrilintide is its combination with semaglutide.
The combination is referred to as CagriSema and brings together:
A 2025 phase 3 REDEFINE 1 trial reported significantly greater body-weight reduction with cagrilintide plus semaglutide compared with placebo over 68 weeks. The study enrolled adults with overweight or obesity without diabetes. New England Journal of Medicine
Importantly, the clinical research concerns specific investigational formulations and doses studied under controlled trial conditions. These findings should not be interpreted as instructions for using an individual research product.
Cagrilintide remains an active area of research.
Novo Nordisk has been advancing cagrilintide as monotherapy as well as part of CagriSema development. Its 2025 annual report described cagrilintide monotherapy development and reported that a REDEFINE 1 sub-analysis showed an average 11.8% body-weight reduction with 2.4 mg cagrilintide compared with 2.3% with placebo at 68 weeks under a treatment-adherence analysis. Novo Nordisk
Clinical research continues to investigate the biological and metabolic effects of the compound.
CagriSema combines cagrilintide and semaglutide.
The combination is being investigated because amylin and GLP-1 signaling may provide complementary effects.
In the REDEFINE 1 phase 3 trial, the estimated mean body-weight change at week 68 was −20.4% with cagrilintide–semaglutide compared with −3.0% with placebo under the trial's specified analysis. Gastrointestinal adverse events were more frequent in the combination group. New England Journal of Medicine
Additional phase 3 studies are continuing to evaluate different populations and dosing approaches.
Metabolic regulation involves communication among:
Amylin signaling represents one component of this complex network.
Laboratory research can examine interactions among these systems using cellular, biochemical, animal, and clinical models.
Body weight is regulated by numerous biological and environmental factors.
Research can investigate:
Studies involving amylin analogues can provide information about the role of amylin-associated signaling in these processes.
However, body-weight outcomes observed in clinical trials should be distinguished from experimental laboratory findings.
Cagrilintide is a peptide-based molecule derived from the biological characteristics of amylin.
Peptide research may investigate:
Structural and analytical studies are important for understanding the characteristics of peptide research materials.
Research laboratories can use analytical methods to characterize peptide materials.
Common approaches include:
Testing can provide information regarding:
Researchers should review batch-specific analytical documentation before beginning experimental work.
High-performance liquid chromatography is widely used for peptide characterization.
Reverse-phase HPLC can separate peptide components according to their interactions with the chromatographic system.
Researchers may use chromatographic analysis to investigate:
HPLC results should be interpreted according to the specific analytical method and laboratory validation parameters.
Mass spectrometry can complement chromatographic testing by providing molecular-mass information.
LC-MS can be particularly useful for investigating:
Combining chromatographic and mass-spectrometric techniques can provide a more comprehensive analytical profile.
Researchers can investigate amylin-related signaling at the cellular level.
Potential techniques include:
Used to investigate receptor activation and ligand interactions.
Can assess downstream signaling proteins.
Can measure gene-expression changes.
Can provide information about protein localization.
Can investigate cellular responses to experimental conditions.
The appropriate method depends on the research hypothesis and biological model.
Good documentation is important for reproducible research.
Researchers should record:
Maintaining detailed records helps laboratories compare experimental runs and investigate unexpected results.
A Certificate of Analysis (COA) can provide batch-specific analytical information.
Depending on the applicable quality-control program, documentation may include:
A COA supports laboratory traceability but should not be interpreted as evidence of clinical efficacy or safety.
Research peptides should be stored according to the manufacturer's current product-specific documentation.
Factors that may influence peptide stability include:
Laboratory personnel should follow appropriate handling practices and consult applicable product documentation and SDS information.
Research material should be handled by appropriately trained laboratory personnel.
Standard laboratory procedures may include:
Researchers should review applicable safety information before conducting laboratory experiments.
Potential areas of investigation include:
Study of amylin-related signaling and physiology.
Investigation of metabolic pathways and energy regulation.
Study of satiety and meal-related signaling.
Investigation of glucose and pancreatic hormone pathways.
Study of amylin-associated receptor signaling.
Investigation of peptide structure and molecular characteristics.
Characterization of peptide identity and purity.
Investigation of metabolic mechanisms across appropriate experimental models.
A well-designed study should include appropriate controls and clearly defined endpoints.
Important considerations include:
Control Groups
Establish a baseline for comparison.
Experimental Model
Choose a model appropriate for the research question.
Defined Endpoints
Determine which physiological, biochemical, or molecular measurements will be evaluated.
Replication
Use appropriate independent replicates.
Analytical Validation
Ensure measurement methods are appropriate for the intended endpoint.
Statistical Analysis
Use suitable statistical methods based on the study design.
A general laboratory workflow may follow:
Material Selection → Analytical Verification → Experimental Model → Controlled Investigation → Sample Collection → Molecular/Physiological Analysis → Statistical Evaluation → Documentation
The precise procedures should be determined by the laboratory's approved research protocol.
Cagrilintide is a long-acting synthetic analogue of the pancreatic hormone amylin that has been investigated in metabolic and obesity-related research.
Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells and involved in meal-related signaling, satiety, gastric emptying, and glucose regulation.
CagriSema is the investigational combination of cagrilintide and semaglutide. It combines amylin and GLP-1 receptor signaling. New England Journal of Medicine
Research areas include amylin signaling, metabolic physiology, appetite biology, glucose regulation, energy balance, body-weight biology, and peptide research.
HPLC, LC-MS, and mass spectrometry can be used to investigate peptide identity, purity, and molecular characteristics.
No. This product is intended for research use only and is not intended for human or veterinary use.
For authoritative scientific information, researchers can consult:
PubMed – Cagrilintide Research
PubMed – Cagrilintide and Semaglutide
ClinicalTrials.gov – Cagrilintide Studies
National Center for Biotechnology Information
The 2025 REDEFINE 1 publication in the New England Journal of Medicine is particularly useful for understanding the clinical research surrounding cagrilintide and its combination with semaglutide. New England Journal of Medicine
Use internal links naturally rather than repeatedly linking the exact product name.
Example:
Researchers interested in additional research peptides can explore the broader collection of laboratory research materials available from LabRat Peptides.
Another example:
For additional information covering peptide science, metabolic research, analytical testing, and laboratory methodologies, visit the LabRat Peptides Research Hub.
You can also add contextual internal links to relevant existing categories such as:
Researchers investigating metabolic signaling, peptide biology, amylin pathways, and related areas can explore the LabRat Peptides Research Collection.
Additional educational information about research compounds, peptide science, laboratory methodologies, and analytical testing is available through the LabRat Peptides Research Hub.
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.
Cagrilintide 10MG is presented as research material for controlled scientific investigation. The information provided is intended for educational and research purposes only and does not constitute medical advice, treatment recommendations, dosing instructions, or instructions for human or veterinary administration.
Clinical research involving cagrilintide has used specific formulations, doses, populations, monitoring procedures, and controlled protocols. Those study conditions should not be interpreted as instructions for using a research product.
Cagrilintide and CagriSema remain subjects of ongoing clinical development. Novo Nordisk reported in February 2026 that CagriSema did not meet the primary non-inferiority endpoint against tirzepatide in the REDEFINE 4 trial, while further development and additional trials continue. Novo Nordisk
Researchers are responsible for complying with applicable laws, institutional requirements, laboratory safety procedures, manufacturer documentation, and approved research protocols.
| Sequence | Available on COA |
| Appearance | White Lyophilized Powder |
| Mol. Weight | 1419.6 g/mol |
| Purity | 99.2% |
| Storage | -20°C or below |
All peptides and research chemicals sold on this site are intended exclusively for in-vitro laboratory research. They are not approved for human consumption, medical treatment, veterinary use, or any in-vivo application.
